Neptune Provides Business Update LAVAL, Quebec, April 29,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Neptune Provides Business Update

LAVAL, Quebec, April 29, 2015 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq: NEPT ) (TSX: NTB ), today provided a business update.

"Since taking over as CEO earlier this year, we have conducted a thorough review of our operations," said Jim Hamilton, President and CEO of Neptune. "Much has been done to strengthen the Corporation and position it for the future.  Our business has a solid foundation, built on science, intellectual property and entrepreneurship.  Moreover, as the krill oil pioneer, with a strong history and solid industry recognition, and based upon my discussions with customers I believe that their doors are very much open to us. We still have much work, but together with a committed management team and board, we are well positioned to resume our leadership role in the phospholipid omega-3 space and I am excited about the opportunities ahead." 

Sherbrooke Plant

"Neptune's Sherbrooke plant has a proven ability to produce at the preliminary targeted capacity of 150 metric tons annually and meet all product label specifications," highlighted Mr. Hamilton. "However, at that level we are seeing some product handling characteristics that are not fully in line with what all our customers expect. As a result, we are slowing the production process down to better deliver on expectations.  Although this allows us to offer a superior product, it is temporarily resulting in higher production costs."

A team, including third-party experts, is determining the cause of the production issue and identifying a longer-term, cost effective solution to enhance product attributes and increase output. "We have engaged outside leading specialists, individuals I have personally worked with in the past, and directionally I am very confident as to where we are going. It is not unusual for a new production facility to experience such hurdles and we are making important progress to resolve the situation as quickly as possible." 

Fourth Quarter Fiscal Year 2015 Preliminary Unaudited Results

Based on preliminary, unaudited financial results for the fourth quarter ended February 28, 2015, Neptune expects revenues to be approximately $4.0 million. As a result of various non-recurring items, largely related to the plant issues, quarterly operational expenses are expected to be significantly higher than originally anticipated. Neptune will be reporting its fourth quarter results on May 27, 2015 after markets close.  

Departure of Chief Financial Officer: André Godin

The Corporation announces the departure of André Godin as Chief Financial Officer of Neptune and its subsidiaries effective immediately. Andre was with Neptune since 2003 and played an active leadership role in all aspects of the organization. "We would like to thank André for all his contributions to Neptune's success over the years and wish him all the best in his future endeavours," said Jim Hamilton, President and CEO. An executive search is currently underway to fulfil his function.

Intellectual Property: '351 Patent

On March 23, 2015 the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) issued a favourable decision, confirming the validity of certain claims under review in Neptune's '351 patent (U.S. Patent: 8,278,351) and triggering on-going royalty payments to Neptune by Aker and Enzymotec. Under a royalty agreement with each of them, payments in the US depended on the PTAB's review of certain claims in Neptune's '351 patent.    

On April 23, 2015 both Aker and Enzymotec filed a request with the same PTAB for a rehearing on the two claims that were shown to be patentable.  If the request is approved, all parties have the opportunity to restate their positions with regards to those two claims at the hearing. A new PTAB decision would follow in the months after the hearing.  As set forth in the settlement agreements entered into with Aker and Enzymotec, on-going royalty payments owed to Neptune should go into escrow until a final decision is rendered by the courts.  

Outlook

"Our overriding objectives are to ensure customers receive a premium product and to optimize plant output in a cost effective manner as quickly as possible," said Mr. Hamilton.  As a result of the lower production levels, sales and expenses for the first quarter ended May 31, 2015 are expected to be negatively impacted. "However, we expect sales and expenses to improve as plant output and efficiencies increase." 

"Given current production issues and various strategic opportunities we have under consideration, we feel that it is prudent and in the best interest of shareholders, to defer any share buybacks related to our Normal Course Issuer Bid."

"Despite our present challenges, we continue to be confident in our business model and our growth prospects. Together with a committed management team and Board, we will drive growth by selling innovative products, building a more agile business and seizing new market opportunities." 

Conference Call Details

Neptune will be holding a conference call on Thursday April 30, 2015 at 8:30 AM (ET) to discuss its business update.

Date: Thursday April 30, 2015
   
Time: 8:30 AM Eastern Time
   
Conference ID:  38167346
   
Call: 1‐877-380-5664 (within Canada & the U.S.)
  1-631-813-4882 (Outside Canada and the U.S.)
  (Please dial in 15 minutes before the call begins)
   
Webcast: A live audio webcast can be accessed at:
  http://neptunekrilloil.com/investors/investor...entations/

An archived recording of the conference call will also be available on Neptune's website shortly after the call.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (''PUFAs''). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune's products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune's head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Through its subsidiary Acasti Pharma Inc. ("Acasti"), in which Neptune holds approximately 48% of the participating and voting rights, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti focuses on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases. Its lead prescription drug candidate is CaPre ® , a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form, which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com , on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune's website at www.neptunebiotech.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors".

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

Neptune Contact: John Ripplinger Investor Relations +1.450.687.2262 neptunebiotech.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading

Top 5 Most Recently Viewed Articles

Eaton Corp's Options Trading Insights and Market Analysis

Updated Category News Views 116

Understanding Eaton Corp's Options Trading Trends Recently, financial analysts have noticed a significant bearish trend when it comes to options trading for Eaton Corp (NYSE: ETN). Investigating the history of options trades has revealed insights into the market sentiment surrounding this industrial giant. A thorough analysis showed that a mere 11% of traders exhibited...

Continue Reading
Celebrating Community Resilience After Pacific Palisades Fires

Updated Category News Views 207

Community Resilience Shines in Pacific Palisades The recent reopening of the Casa Gateway affordable housing complex in Pacific Palisades brings a heartwarming sense of relief to many residents who faced the devastating impact of fires. Amidst the recovery efforts, stories of gratitude and hope shine through, demonstrating the importance of community support and...

Continue Reading
Stellantis Makes Bold Move with $41 Million Investment for Efficiency

Updated Category News Views 225

Stellantis Invests $41 Million for Enhanced Parts Delivery Stellantis (NASDAQ: STLA), the parent organization of popular automotive brands such as Jeep and Dodge, is taking significant steps towards improving its logistics capabilities with a substantial $41 million investment. This financial commitment is part of a broader strategy to modernize its parts distribution...

Continue Reading
Navigating the Shifts in Money Market Dynamics and Bank Reserves

Updated Category News Views 137

Understanding Current Dynamics in Money Markets The landscape of liquidity in the money markets is currently characterized by ample conditions. However, experts anticipate a reduction in bank reserves in the months ahead, leading to a potential tightening of conditions. With ongoing activity in market repurchase agreements (repo) and a robust issuance of treasury bills,...

Continue Reading
Harnessing AI and Human Intelligence for Personal Growth

Updated Category News Views 329

AI Happiness Accelerator Empowers Personal Growth Imagine if you could optimize your thoughts and emotions just like improving a website’s performance. The AI Happiness Accelerator (AHA) aims to do exactly that by leveraging cutting-edge Generative AI tools. Co-founder and Chief Information Officer Amy Chang emphasizes that success in all areas—personal, relational,...

Continue Reading